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tions (i.e. PIER trial). The model assumes that patients discontinue treatment after the 
second year of treatment. Costs related to drug acquisition, administration, monitor-
ing costs and blindness were considered in the analysis (2015). This model predicted: 
blind-years, quality-adjusted life-years (QALYs), and the direct costs from a payer 
perspective. Results: Treatment without delay was found to be more beneficial 
compared to “with delay” treatment in terms of QALYs (4,487 vs. 4,190) and blind-years 
(1,084 vs. 1,511). The total lifetime cost was calculated to be € 235 higher in patients 
treated without any delay, resulting in an ICER of € 790 per QALY gained (well-below 
the threshold of € 17,000). The higher drug acquisition cost observed in “without delay” 
arm was partially offset by the increased non-medical direct cost related to the “with 
delay” arm. ConClusions: Ranibizumab treatment of wAMD without delay seems 
to be a strongly cost-effective strategy in Greece.
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objeCtives: Chronic spontaneous urticaria (CSU) is characterised by rapid appear-
ance of wheals, angioedema or both, with no obvious cause and with symptoms 
lasting for more than six weeks; CSU has a demonstrable negative impact on patient 
quality of life and societal productivity. The objective of this study was to assess 
the cost-utility of omalizumab compared with continued standard of care (SOC) 
for the treatment of patients with moderate or severe CSU with an inadequate 
response to SOC, from the UK societal perspective. Methods: A Markov model 
was developed, defined by five disease severity health states and three additional 
states for relapse, spontaneous remission and death. The model considered 6 month 
courses of omalizumab treatment, with re-treatment upon relapse (relapse defini-
tion: UAS7≥ 16) and early discontinuation of non-responders (definition of response: 
UAS7≤ 6). Clinical and cost inputs were derived from omalizumab trials and pub-
lished sources; productivity inputs were informed by a non-interventional study 
and average earnings data. The base case considered a 20-year time horizon, and 
cost-utility was expressed as an incremental cost-effectiveness ratio (ICER). Scenario 
analyses included no early discontinuation of non-responders and an altered 
definition of response (UAS7< 16). Results: In the base case analysis, the deter-
ministic ICER was £3,183, with omalizumab being associated with increased costs 
and increased benefit relative to SOC. Probabilistic sensitivity analysis supported 
this result. Individual scenarios without early discontinuation of non-responders 
and adjusting the definition of response had little impact on Results(ICERs £4,409 
and £5,304, respectively). Further sensitivity analyses demonstrated robustness of 
Resultsto changes in key model parameters and inputs. ConClusions: To our 
knowledge, this is the first economic evaluation of omalizumab in CSU from a UK 
societal perspective. Omalizumab was associated with consistently low ICERs across 
a range of different scenarios, demonstrating omalizumab to represent a treatment 
option with societal benefit for CSU in the UK.
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objeCtives: Chronic spontaneous urticaria (CSU) is a skin disease, with itchy hives 
that last for at least 6 weeks without an obvious external trigger. Omalizumab has 
been shown to diminish clinical symptoms and signs. The objective of this study 
was to determine the cost-effectiveness of omalizumab relative to cyclosporine 
and standard of care (up to 4 times the daily dose of H1-antihistaminics) for the 
Netherlands. Methods: A Markov model was used in this study. The model’s set-
tings and characteristics of the Dutch patient population were based on an online 
survey among clinical experts. These values were validated during a clinical expert 
committee meeting. The GLACIAL trial was used to describe transition probabilities. 
Data on health care consumption, quality of life and productivity losses were derived 
from medical records and a survey among 93 Dutch CSU patients. Health care con-
sumption was valued using prices from the Dutch costing manual. Utilities were 
derived from EQ-5D and calculated using Dutch tariffs. Productivity losses were val-
ued using Dutch wage rates. Comparator treatments were cyclosporine and standard 
of care. Uncertainty was assessed by one-way sensitivity analyses and probabilistic 
sensitivity analyses. Results: Omalizumab was more effective than cyclosporine 
(incremental QALYs: 11.3). Incremental costs for omalizumab were € 51.052, result-
ing in an ICER of € 4.510 per QALY gained. Compared to standard of care, incremental 
QALYs for omalizumab were 9.2 and incremental costs were € 161.342 (ICER of € 17.502/
QALY gained). Productivity costs played an important role in the value of the ICER. 
Probabilistic sensitivity analyses resembled the Resultsfrom the deterministic analy-
ses. ConClusions: Omalizumab is cost-effective compared to both cyclosporine and 
standard of care. The ICER is well below the implicit cost-effectiveness threshold in 
the Netherlands, which ranges from € 20.000-80.000 per QALY.
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objeCtives: To conduct a cost-utility analysis of ranibizumab versus aflibercept for 
the treatment of patients with visual impairment due to diabetic macular edema 
(DME) in the Greek setting. Methods: A Markov model was adapted to compare the 
use of ranibizumab 0.5mg (pro re nata-PRN and treat & extend-T&E) to aflibercept 
2mg (every 8 weeks after 5 initial doses) in DME. Patients transitioned at a 3-month 
cycle among nine specified health states (including death) over a lifetime horizon. 
Transition probabilities, utilities as well as DME-related mortality incorporated in 
the model were extracted from relative clinical trials, a network meta-analysis and 
other published studies. The drug acquisition and administration costs as well as 
the costs of blindness and laser surgery were also incorporated in the analysis. The 
analysis was conducted from payer perspective and as such only costs reimbursed 
by the payer were considered (year 2014). Treatment costs and health outcomes 
were discounted by 3.5% annually. The incremental cost per quality-adjusted life 
year (QALY) gained and the net monetary benefit was the main outcome measures. 
Sensitivity analysis was conducted to test robustness of the model. Results: Τhe 
use of PRN and T&E ranibizumab regimens were shown to be cost saving compar-
ing to aflibercept by € 2,824 and € 22, respectively, and more beneficial in terms of 
QALYs gained (+0.05) and time without visual impairment (0.031 and 0.034 years), 
thereby dominating aflibercept. Moreover, ranibizumab used as PRN or T&E resulted 
in a net monetary benefit of € 3,984 and € 1,278, respectively. Sensitivity analysis 
revealed that the net monetary benefit for each regimen remained positive for all 
tested scenarios. ConClusions: Both PRN and T&E ranibizumab regimens were 
more beneficial and less costly compared to aflibercept for the management of 
DME. Hence, ranibizumab seems to be a dominant option for the treatment of visual 
impairment due to DME in the Greek setting.
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objeCtives: To estimate the incremental cost utility ratio (ICUR) for ingenol mebu-
tate vs imiquimod 5% for actinic keratosis (AK) patient’s treatment on the face 
and scalp, in Spain. Methods: A Markov model was used to simulate AK patient 
treatment evolution for a 5-year horizon from the Spanish National Health System 
(NHS). Duration of ingenol mebutate treatments was 3 days and 12 days for imiqui-
mod 5%. Effectiveness measure was total clearance rate obtained from indirect 
mixed comparisons (42.24% for ingenol mebutate and 44.54% for imiquimod) and 
adjusted according compliance (90% for ingenol mebutate and 60% for imiquimod). 
Annual recurrence rate (20%) derived from literature. Annual discount rate of 3% 
was applied for costs and outcomes. Total cost estimation (€ ,2015) included: drug 
(retail price VAT included with mandatory deduction), and dermatology visits cost 
(for adverse events and disease management).Utilities values (0.986 for AK and 1 
for clearance) were used to derive quality-adjusted-life years (QALY). Probabilistic 
and deterministic sensitivity analyses were performed to confirm the robustness of 
the obtained results. Results: Ingenol mebutate showed higher effectiveness than 
imiquimod 5%, 0.535 vs 0.503 total gained clearances and 4.451 vs 4.449 total QALYs 
and accounted higher total costs, € 551.50 (46% drug cost) versus € 527.89 (36% drug 
cost) compared to imiquimod 5%. Estimated ICUR was € 10.906/QALY gained with 
ingenol mebutate vs imiquimod 5%. In probabilistic sensitivity analysis performed, 
78% of simulations yielded an ICUR below € 30,000/QALY for ingenol mebutate versus 
imiquimod. ConClusions: Ingenol mebutato vs imiquimod 5% was an efficient 
alternative for NHS for patients with AK, on face and scalp, considering an accept-
able threshold of € 30,000/QALY.
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objeCtives: To examine the impact of delay between indication to treat and injection 
of ranibizumab for the management of age-related macular degeneration (wAMD), in 
Greece. Methods: A Markov model was developed to estimate, in a lifetime horizon, 
the clinical and cost outcomes related to treatment with ranibizumab 0.5mg on a 
pro re nata protocol: a) “without delay” and b) “with delay” between medical indica-
tion and treatment administration. At monthly cycles, patients’ visual acuity could 
increase by 3 lines, remain the same, or decrease by 3 lines. As for the “without delay” 
arm, the number of injections and transition probabilities were obtained from the 
CATT trial, while for the “with delay” arm, a one-month delay at first treatment was 
assumed, based on local experts estimation, and then the delay at re-treatment was 
indirectly modeled by applying number of injections and transition probabilities as 
obtained from clinical trials evaluating the efficacy of a quarterly protocol of injec-
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for SEC and UST were 6.84, 2.87, € 54,428 and 6.79, 2.08, € 54,572, respectively. 
Probabilistic sensitivity analysis indicated robustness in the Conclusionsof domi-
nance/highly cost-effective approach for SEC vs. UST. ConClusions: Applying 
stricter criteria for response (i.e., PASI≥ 75 instead of PASI≥ 50) for treatment dis/
continuation for highly efficacious PSO therapy (SEC) Resultsin overall greater 
QALYs and cost savings for the health-care system.
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objeCtives: There are limited data on healthcare resource utilisation associated 
with inadequately controlled chronic spontaneous (idiopathic) urticaria (CSU/
CIU) patients. ASSURE-CSU is an observational, multinational study conducted to 
identify and quantify burden of illness in these patients. Data on resource utilisa-
tion for Canada, Germany, UK and the Netherlands are summarised. Methods: 
This study included a 1-year retrospective medical record abstraction and a cross-
sectional patient-reported outcomes survey. Adult CSU/CIU patients with disease 
persisting for ≥ 12 months despite treatment were assessed. Data on resource 
utilisation were extracted from patient medical records, and reported descrip-
tively. Results: Medical records were abstracted for 99 patients each in Canada 
and the Netherlands, 100 in Germany and 83 in the UK. In Canada, 83% patients 
had one or more visits to a health care professional (HCP) with a total mean (SD) 
of 3.1 (2.57) annual visits. In the prior 12 months, visits to allergists and derma-
tologists were reported by 72% and 11% patients. In Germany, 52% patients visited 
HCPs [annual visits: 3.3 (3.81)]. Hospitalisations and emergency room (ER) visits 
were reported by 18% and 15% patients. Allergists and dermatologists were visited 
by 33% and 31% patients. In UK, 86% patients visited HCPs [annual visits: 3.7 (2.68)]. 
Dermatologists were seen by 54% patients, allergists by 30% and hospital nurses 
by 10%. HCPs were visited by 87% patients in the Netherlands [annual visits: 4.1 
(3.87)]. Visits to dermatologists, allergists and other consultants were reported by 
51%, 42% and 13% patients. ER visits and hospitalisations were less frequent in 
Canada, the UK and the Netherlands compared with Germany. ConClusions: 
This is the first study to quantify resource utilisation associated with inadequately 
controlled CSU/CIU. The types of medical resources differ among the countries 
depending on the local healthcare specificities. Resource utilisation pattern was 
primarily outpatient but varied across countries.
SenSory SyStemS diSorderS – Patient-reported outcomes & Patient  
Preference Studies
PSS53
eConomiC bUrden of ChroniC SPontaneoUS UrtiCaria and PSoriaSiS: 
PatientS PerSPeCtive from eUroPe
Vietri J1, Tian H2, Gabriel S2, Balp M3, Khalil S3, Zuberbier T4
1Kantar Health, Horsham, PA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 
USA, 3Novartis Pharma AG, Basel, Switzerland, 4Allergie-Centrum-Charité, Berlin, Germany
objeCtives: Chronic urticaria (CU) (or chronic hives) can be inducible or spontane-
ous (also known as idiopathic urticaria) (CSU/CIU). Data supporting the impact of 
CSU/CIU on patients and comparison with other dermatological diseases are scarce. 
This study evaluated economic burden associated with CU relative to psoriasis (PsO) 
overall and different severity levels of PsO among the adults in 5 European (France, 
Germany, Italy, Spain and UK) countries. Methods: Data from patients diagnosed 
with chronic hives (proxy for CSU) and PsO were collected in the National Health 
and Wellness Survey (NHWS). Outcome measures included the Work Productivity 
and Activity Impairment (WPAI) questionnaire and self-reported healthcare use in 
prior 6 months. Generalized linear models with different link functions were used 
to compare patients with CU vs. overall PsO (includes all severity levels) and CU 
vs. moderate-severe-PsO, controlling for patient characteristics. Results: Study 
included 769 CU patients and 7,857 PsO patients (26.9% moderate-severe). CU 
patients reported non-significant higher rate ratio (RR) of absenteeism (RR= 1.31), 
presenteeism (1.15) and overall work impairment (1.15) than overall PsO, however, 
activity impairment was significantly higher among CU patients (1.21; p< 0.05). 
The rates of work and activity impairment were similar between CU and moder-
ate-severe-PsO patients (RR: absenteeism; 0.99, presenteeism; 0.97, overall work 
impairment; 0.97 and activity impairment; 1.08) (all p= NS). Rate of healthcare vis-
its were higher among CU than overall PsO (RR: HCP visits; 1.16, ER visits; 2.13, 
Hospitalizations; 1.94, all p< 0.001) and also than moderate-severe-PsO patients (RR: 
HCP visits;1.07, ER visits;1.77, Hospitalizations;1.47, all p< 0.001). ConClusions: 
Patients with CU and PsO report a similar negative impact on work ability. Compared 
to overall PsO patients with CU have a significantly higher impact on daily activities 
and non-significant higher impairment on work components. The impact on work 
and activities is similar among CU and moderate-severe PsO. CU patients report 
significantly higher use of medical resources than Pso.
objeCtives: To estimate the incremental cost-utility ratio (ICUR) for ingenol mebu-
tate vs diclofenac 3% for actinic keratosis (AK) patient’s treatment on the face and 
scalp, and trunk and extremities, in Spain. Methods: A hypothetical cohort of 73 
aged AK patients was simulated for a 5-year time horizon with a Markov model. 
Duration of treatments was 3 days (face-scalp) and 2 days (trunk-extremities) for 
ingenol mebutate and 90 days (face-scalp and trunk-extremities) for diclofenac. 
Total clearances rates (42.24% and 34.07% for ingenol mebutate and 24.64% and 
25.07% for diclofenac on face-scalp and on trunk-extremities, respectively) obtained 
from indirect mixed comparisons and adjusted according compliance were used 
as effectiveness measure. Annual recurrence rate (20%) derived from literature. 
The perspective of the Spanish National Health System (NHS) was choosen. Total 
cost estimation (€ ,2015) included: pharmaceutical cost (retail price VAT included 
with mandatory deduction), and dermatology visits cost (for adverse events and 
disease management).A 3% annual discount rate was applied for costs and out-
comes. Utilities values (0.986 for AK and 1.00 for clearance) were used to derive 
quality-adjusted-life years (QALY). Several sensitivity analyses were performed to 
test model robustness. Results: Ingenol mebutate showed higher effectiveness, 
with 0.192 incremental clearances and 0.011 incremental QALYs (face-scalp), and 
0.129 incremental clearances and 0.007 incremental QALYs (trunk-extremities) 
compared to diclofenac. Total costs accounted were € 551.50 and € 622.27 (46% drug 
cost) for ingenol mebutate, compared to € 849.11 and € 844.93 (54% drug cost) for 
diclofenac (for face-scalp and trunk-extremities, respectively). Ingenol mebutate 
versus diclofenac 3% was dominant on face-scalp and trunk-extremities AK treat-
ment. Further, ingenol mebutate remained a dominant option in 96% (face-scalp) 
and 91% (trunk-extremities) of the 1,000 MonteCarlo simulations of probabilistic 
sensitivity analysis. ConClusions: Ingenol mebutate was a dominant strategy for 
Spanish NHS, compared to diclofenac 3%, for treatment of patients with AK both, 
face-scalp and trunk-extremities.
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objeCtives: Secukinumab (SEC300), an IL-17A antibody, was recently approved as 
highly effective therapy for moderate-to-severe plaque psoriasis (PSO). We examined 
the cost-effectiveness of SEC300 compared against other systemic biologic drugs: 
adalimumab (ADA), etanercept (ETA), infliximab (INF), ustekinumab (UST) 45 and 
90 mg, and standard of care (SOC - cyclosporine and methotrexate) for plaque pso-
riasis, in the Italian National Health System (NHS) setting. Methods: A previous 
cost-effectiveness model was adapted to the Italian healthcare setting. The model 
was designed to consider the clinical benefits, resource use and costs related to 
SEC300. A decision tree reflecting response to treatment (PASI change < 50, 50-75, 
75-90, 90-99, 100) fed into a long-term Markov model with health states related 
to treatment continuation, dropout, and death. Clinical data (PASI change scores, 
percentage of adverse events, discontinuation rate) and utility scores were derived 
from clinical trials as well as from published evidence on Italian patients. The per-
spective of the model is the Italian NHS, therefore only direct medical costs (drug 
prices, inpatient and outpatient hospital tariffs, etc.) were taken in account. Both 
costs and benefits were discounted at 3% according to Italian National Guidelines 
for Health Economics Evaluations. Incremental cost-effectiveness ratios (ICERs) 
were calculated. Results: At 10 years, SEC300 is a dominant (less costly and more 
effective) option compared with UST45 and UST90. It is a cost-effective option – with 
a threshold < € 50,000/QALY gained as per National Health Economics Evaluation 
Guidelines – vs. ADA, IFN, ETA, and SOC with an ICERs of € 37,252, € 48,949, € 21,943 
and € 41,896, respectively. The sensitivity analysis demonstrated the robustness of 
model results. ConClusions: The model shows that SEC300 is a costΤeffective 
option when compared to other biologic agents and SOC currently funded by NHS 
in Italy for the treatment of moderate-to-severe plaque psoriasis.
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objeCtives: Secukinumab (SEC), an IL-17A antibody, is a new highly effective 
therapy for moderate-to-severe plaque psoriasis (PSO). Ustekinumab (UST) is 
reimbursed in the Czech Republic under the condition of ≥ PASI50 response at 
week 16. We estimated the cost effectiveness of SEC vs. UST based on differ-
ent PASI response (dis/continuation) criteria; PASI≥ 75 for SEC and PASI≥ 50 for 
UST. Methods: A decision tree reflecting response to treatment (PASI change 
< 50, 50-75, 75-90, 90-99, 100) fed into a long-term Markov model with health states 
related to treatment continuation, dropout, and death. Responders at week 16 
(defined as PASI≥ 75 for SEC, PASI≥ 50 for UST) continued on biologic treatment. 
Non-responders and drop-outs were switched to standard-of-care (MTX, CyA, 
emollients). A health-care system perspective with 3% discount rate was adopted. 
Dosing schedule for maintenance treatment for SEC and UST as 12.0 and 4.35 
doses per year was calculated. Baseline patient characteristics and efficacy data 
were derived from the CLEAR study, a head-to-head 52-week superiority trial (SEC 
300 mg vs. UST 45/90 mg). Long-term treatment resistance and dropout were 
modelled by assuming a 20% annual discontinuation rate. Utility weights for each 
health state were calculated from EQ-5D measures from the SEC clinical pro-
gram. Results: With a 10-year time horizon, SEC treatment gains 0.05 QALYs and 
0.80 years in PASI≥ 90 with € 144 in cost savings vs. UST, reflecting dominance of 
SEC vs. UST. Absolute (discounted) QALYs, years in ≥ PASI90 and costs (discounted) 
